StockNews.AI
LENZ
StockNews.AI
161 days

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

1. LENZ Therapeutics will host a webcast on March 19, 2025. 2. The company will report its fourth quarter and full year 2024 financial results. 3. LENZ's LNZ100 targets presbyopia, affecting 1.8 billion globally. 4. FDA has set an action date of August 8, 2025 for LNZ100. 5. LENZ aims to commercialize an ideal presbyopia solution.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive developments like a webcast and upcoming FDA action date enhance investor confidence, similar to past successful biotech launches.

How important is it?

Key milestones such as earnings reports and FDA actions are critical for investor sentiment and market positioning.

Why Long Term?

The FDA decision will significantly influence LENZ's future growth and market entry beyond 2025.

Related Companies

VRTXREGNAMGN
March 11, 2025 08:00 ET  | Source: LENZ Therapeutics, Inc. SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, March 19, 2025, at 4:30 p.m. EST to report its fourth quarter and full year 2024 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 9147301. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event. About LENZ TherapeuticsLENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com. Contacts:Dan Chevallard LENZ TherapeuticsIR@LENZ-Tx.com

Related News